<!DOCTYPE html>
<html lang="en-us">
  <head>
    <meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<meta name="generator" content="Hugo 0.30.2" />


<title>Surrogate Oncogene Paper is Published - Personal Website for Ted Laderas, PhD</title>
<meta property="og:title" content="Surrogate Oncogene Paper is Published - Personal Website for Ted Laderas, PhD">



  







<link rel="stylesheet" href="/css/fonts.css" media="all">
<link rel="stylesheet" href="/css/main.css" media="all">



  </head>
  <body>
    <div class="wrapper">
      <header class="header">
        <nav class="nav">
  <a href="/" class="nav-logo">
    <img src="/images/logo.png"
         width="50"
         height="50"
         alt="Logo">
  </a>

  <ul class="nav-links">
    
    <li><a href="/about/">About</a></li>
    
    <li><a href="/cv/">CV</a></li>
    
    <li><a href="/teaching/">Teaching</a></li>
    
    <li><a href="http://github.com/laderast">GitHub</a></li>
    
    <li><a href="https://twitter.com/tladeras">Twitter</a></li>
    
  </ul>
</nav>

      </header>


<main class="content" role="main">

  <article class="article">
    
    <span class="article-duration">2 min read</span>
    

    <h1 class="article-title">Surrogate Oncogene Paper is Published</h1>

    
    <span class="article-date">2015/12/23</span>
    

    <div class="article-content">
      <p>My dissertation paper, <a href="http://journal.frontiersin.org/article/10.3389/fgene.2015.00341/abstract">A Network-Based Model of Oncogenic Collaboration for Prediction of Drug Sensitivity</a> is now published! Here&rsquo;s a lay summary:</p>

<blockquote>
<p>One outstanding issue in analyzing genomics in the context of personalized medicine is the incorporation of rare
or infrequent genetic alterations (copy number alterations and somatic mutations) that are observed in individual &gt; patients. We hypothesize that these mutations may actually &lsquo;collaborate&rsquo; with known oncogenes in the genesis of
tumors through their interactions. In order to show this effect, we assess whether these interacting rare
mutations cluster around known oncogenes and assess these mutational clusters, which we term <em>surrogate
oncogenes</em>. We assess their statistical significance using a simple model of mutation. We show that surrogate
oncogenes are predictive of drug sensitivity in breast cancer cell lines. Additionally, they are prevalent in
three different cancer cohorts (Breast, Glioblastoma, and Bladder Cancer) from The Cancer Genome Atlas. Within
the Breast Cancer and Bladder Cancer populations, surrogate oncogenes are predictive of overall patient
survival. The chief strength of the surrogate oncogene approach is that it can be run at a single-patient
level in comparison to other methods of assessing mutational significance.</p>
</blockquote>

<p>If you&rsquo;re interested in learning more, you can check out the <a href="https://tladeras.shinyapps.io/surrogateShiny/">Surrogate Oncogene Explorer</a> in order to understand the nature of surrogate oncogenes, and my <a href="https://github.com/laderast/surrogateMutation">R/Bioconductor Package on GitHub</a> if you&rsquo;d like to try out the analysis.</p>

<p>There&rsquo;s a follow-up paper that I&rsquo;m working on that I&rsquo;m very excited about. More news soon.</p>

    </div>
  </article>

  


</main>

      <footer class="footer">
        <ul class="footer-links">
          <li>
            <a href="/index.xml" type="application/rss+xml" target="_blank">RSS feed</a>
          </li>
          <li>
            <a href="https://gohugo.io/" class="footer-links-kudos">Made with <img src="/images/hugo-logo.png" width="22" height="22"></a>
          </li>
        </ul>
      </footer>

    </div>
    

    

    
  </body>
</html>

